Morepen Laboratories Ltd Sees Exceptional Volume Surge Amid Strong Price Gains

Trading Volume and Price Action Overview

On 1 Oct 2026, Morepen Laboratories Ltd (symbol: MOREPENLAB) emerged as one of the most actively traded stocks by volume on the Indian equity markets. The total traded volume reached an impressive 1.81 crore shares, translating to a total traded value of approximately ₹236.82 crores. This volume figure significantly exceeds the stock’s recent averages, signalling heightened investor participation.

The stock opened at ₹125.90, close to the previous close of ₹125.99, but quickly gained momentum to touch an intraday high of ₹135.29, representing a 6.2% rise from the open. The last traded price (LTP) stood at ₹132.86 as of 10:38 AM, reflecting a strong upward trajectory. Notably, the stock hit a new 52-week high of ₹133.80 during the session, underscoring the bullish sentiment.

Technical and Moving Average Insights

Morepen Laboratories is currently trading above all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — indicating a sustained uptrend across multiple timeframes. This technical positioning often attracts momentum traders and institutional investors looking for stocks with strong relative strength.

The stock’s narrow intraday trading range of just ₹0.30 around the weighted average price suggests that most volume was transacted near the lower end of the day’s price band. This pattern can be interpreted as accumulation by buyers absorbing selling pressure, a positive sign for future price stability.

Investor Participation and Delivery Volumes

Investor participation has surged notably, with delivery volumes on 30 Sep 2026 reaching 92.22 lakh shares. This figure represents a 117.21% increase compared to the five-day average delivery volume, signalling strong conviction among long-term investors. Higher delivery volumes typically indicate genuine buying interest rather than speculative intraday trading.

Liquidity remains adequate for sizeable trades, with the stock’s traded value comfortably supporting trade sizes up to ₹4 crores based on 2% of the five-day average traded value. This liquidity profile is favourable for institutional investors seeking to build or exit positions without excessive market impact.

Relative Performance and Sector Comparison

Morepen Laboratories outperformed its Pharmaceuticals & Biotechnology sector peers by a significant margin, delivering a 5.19% return on the day compared to the sector’s marginal decline of 0.16%. The broader Sensex also declined by 0.20%, highlighting the stock’s relative strength amid a generally weak market environment.

The stock has been on a consecutive gain streak for two days, accumulating a total return of 12.63% during this period. This momentum is indicative of renewed investor confidence, possibly driven by positive developments or improving fundamentals within the company or sector.

Mojo Score and Rating Upgrade

MarketsMOJO’s proprietary Mojo Score for Morepen Laboratories currently stands at 64.0, categorising the stock with a “Hold” grade. This represents an upgrade from the previous “Sell” rating issued on 3 Aug 2026, reflecting improved outlook and technical parameters. The upgrade signals a cautious but optimistic stance, suggesting that while the stock shows promise, investors should monitor developments closely.

With a market capitalisation of ₹7,041 crores, Morepen Laboratories remains classified as a small-cap stock, which often entails higher volatility but also greater growth potential compared to large-cap peers.

Accumulation and Distribution Signals

The combination of rising delivery volumes, trading above key moving averages, and a narrow price range with volume concentrated near the day’s low price point suggests strong accumulation by institutional and retail investors alike. This pattern typically precedes further price appreciation as supply is absorbed and demand strengthens.

Investors should note that the stock’s recent gap-up opening of 5.99% on 1 Oct 2026 further confirms bullish sentiment, often driven by positive news flow or upgrades in analyst outlooks.

Outlook and Investor Considerations

While the recent volume surge and price appreciation are encouraging, investors should remain mindful of the inherent risks associated with small-cap stocks, including higher volatility and sensitivity to market sentiment. The “Hold” Mojo Grade suggests that Morepen Laboratories is currently fairly valued relative to its fundamentals and technicals, but further catalysts will be needed to sustain the upward momentum.

Market participants should watch for quarterly earnings updates, regulatory developments, and sectoral trends that could influence the stock’s trajectory. Additionally, monitoring delivery volumes and price action in coming sessions will provide further clues on whether accumulation continues or profit-taking emerges.

Given the stock’s liquidity profile and strong relative performance, Morepen Laboratories remains an attractive candidate for investors seeking exposure to the Pharmaceuticals & Biotechnology sector with a growth tilt, provided they maintain appropriate risk management.

Summary

Morepen Laboratories Ltd’s exceptional trading volume of over 1.8 crore shares and a 4.68% price gain on 1 Oct 2026 highlight a significant shift in market sentiment. The stock’s technical strength, rising delivery volumes, and upgrade in Mojo Grade from Sell to Hold reinforce the narrative of renewed investor interest and accumulation. Outperforming both its sector and the broader market, Morepen Laboratories is poised for further attention, though investors should weigh the risks typical of small-cap equities.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →